Dissolve with 2.5 mL of distilled water when the solution will be used, then split into smaller packages, store at -20
Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals
Prez R, Castilla-Cortzar I, Nez M, Prado A, Mirpuri E, Garca M, Gonzlez Barn S, Picardi A: IGF-I does not improve fat malabsorption in cirrhotic rats
Questions can be answered by emailing or calling our support staff at 561-235-0100 or [email protected] , and you will get answers to all your questions
Functional transformation of C-reactive protein by hydrogen peroxide
Alternative treatments should be considered by pregnant women, nursing mothers, and people with asthma, sulfite allergies, or specific kidney/liver conditions
